An enzyme-linked immunosorbent assay (ELISA) for the detection and quantita
tion of soluble alpha 1 beta 1 integrins (s alpha 1) in human serum samples
was developed. Solid phase-bound anti-al integrin monoclonal antibody (mAb
) TS2/7 was used to capture sal,and mAb 1B3.1 was used to detect the immobi
lized integrin. An extract of human placenta (PE) containing 340 ng/mL of V
LA-1 molecules served as a positive control, and serum samples from normal
donors and patients were assayed. Optimal binding of anti-al integrin mAb 1
B3.1,expressed as specific optical density (OD), was obtained when a 5 mu g
/mL solution of anti-at integrin "capture" mAb TS2/7 was immobilized to the
wells and the PE was added. Solutions of albumin or collagen, in contrast,
did not result in binding, confirming the specificity of the assay for sat
. Furthermore, the specific OD of the wells correlated directly with the co
ncentration of PE. A concentration of sat above that of a 1:100 dilution of
PE--that is, >3.4 ng/mL of integrin, in which the intra-assay correlation
of variance was <5.7%, was found in 5 of 8, 3 of 8, and 6 of 9 serum sample
s from normal individuals, patients with connective tissue diseases (CTD),
and patients with liver diseases (LD), respectively. These results suggest,
for the first time, that sat are present in healthy and diseased human ser
um.